# Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer

Source: https://onco.cc/trials/nct07806773/  
OnCo record `nct07806773` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in lung cancer, run by Tubulis GmbH, not yet recruiting.

## Summary

Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer is a phase 2, randomised interventional study registered as NCT07806773 by Tubulis GmbH, with a registry enrolment figure of 80 participants, started 2026-11 and due to reach its primary completion in 2029-05. Interventions recorded: TUB-040. Conditions listed: NSCLC; Non Small Cell Lung Cancer. Primary outcome: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs); Overall Response Rate (ORR). Lung eligibility wording from the registry: "Mixed histology NSCLC (eg, small cell lung cancer/NSCLC) or histology other than adenocarcinoma". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07806773
- Phase: 2
- Setting: A Randomized, Open-label, Phase 2a Dose Optimization Study of TUB-040 (a NaPi2b Antibody-drug Conjugate) in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer
- Sponsor: Tubulis GmbH
- Enrolled: 80

## Sources

- ClinicalTrials.gov NCT07806773: https://clinicaltrials.gov/study/NCT07806773

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- companies: [Tubulis (Gilead)](https://onco.cc/companies/tubulis/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07806773.json